FIGURE 4 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma

Increased levels of IFN signaling components and changes in ICD biomarkers or chemokines/cytokines on treatment of TCL cell lines with decitabine and tolinapant. A, Western blots of mouse BW5147 cell lysates prepared after 48 hours treatment with different concentrations of decitabine without and with 1 µmol/L tolinapant. B, IFNγ MSD assay of H9 cell supernatants collected after 48 hours treatment with different concentrations of decitabine. C, log₂ fold increase (relative to DMSO control) in 41 chemokines/cytokines from BW5147 cell supernatants taken 48 hours after treatment with 1 µmol/L DAC, 1 µmol/L tolinapant, or a combination of both measured by Luminex assay. D, Data from C showing raw data for IP-10 (CXCL10) levels. E, HMGB1 ELISA assay of BW5147 cell supernatants collected after 24 hours treatment with different concentrations of decitabine with 0, 0.1, or 1 µmol/L tolinapant.